The trend towards less invasive surgery using smaller incisions and endoscopes reduces a surgeon's ability to see and feel tissue directly. This loss of traditional tactile and visual feedback creates a critical need for new tools. Fluorescence-guided surgery is not just an improvement but a necessary replacement for these lost senses.
Because cancer cells can be genetically different even a centimeter apart within the same tumor, a single targeting agent will inevitably miss some malignant tissue. The solution is a 'cocktail' of multiple tumor-targeted dyes, each targeting a different marker, to ensure visualization of virtually all cancer variants in a patient.
To demonstrate value to regulators, the clinical trial design has surgeons first remove all cancer identifiable via sight and touch. Only then is the fluorescent light turned on, starkly revealing missed malignant tissue. This method provides immediate, undeniable evidence of the technology's superiority and its ability to prevent recurrence.
Fluorescence-guided surgery will evolve beyond simply lighting up tumors. Dr. Phil Low's team is developing different colored dyes to simultaneously highlight healthy, critical structures like nerves and ureters. This 'surgery by colors' approach aims to prevent accidental severing and reduce major complications like incontinence or impotence.
Dr. Phil Low created a powerful feedback loop for commercialization by focusing 90% of his time on academic research and hiring experts to run his companies. He then used grants from those companies to fund his university lab, giving the companies first-refusal rights on any resulting patents, creating a direct innovation pipeline.